Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone ( BV ‐ CHEP ) for the treatment of aggressive adult T‐cell leukaemia/lymphoma

Documenti analoghi

• A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial
  di: Cecilia Carpio, et al.
  Pubblicazione: (2025)
• Long‐term follow‐up of dose‐dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second‐line treatment of relapsed/refractory classical Hodgkin lymphoma
  di: Ryan C. Lynch, et al.
  Pubblicazione: (2025)
• Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen
  di: Olayinka Okeleji, et al.
  Pubblicazione: (2024)
• Primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma initially demonstrating near‐complete metabolic response to BV‐CHEP
  di: Tristen Tze Wei Ng, et al.
  Pubblicazione: (2025)
• Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy
  di: Arthur Matthys, et al.
  Pubblicazione: (2024)